These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells. Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503 [TBL] [Abstract][Full Text] [Related]
6. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis. Kazemi A; Safa M; Shahbazi A Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539 [TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708 [TBL] [Abstract][Full Text] [Related]
8. The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells. Ghasemimehr N; Farsinejad A; Mirzaee Khalilabadi R; Yazdani Z; Fatemi A Biomed Pharmacother; 2018 Oct; 106():1742-1750. PubMed ID: 30170357 [TBL] [Abstract][Full Text] [Related]
9. Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101. Riyahi N; Safaroghli-Azar A; Sheikh-Zeineddini N; Sayyadi M; Bashash D Cancer Invest; 2019; 37(7):311-324. PubMed ID: 31412710 [TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. Badinloo M; Esmaeili-Mahani S Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575 [TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. De Milito A; Iessi E; Logozzi M; Lozupone F; Spada M; Marino ML; Federici C; Perdicchio M; Matarrese P; Lugini L; Nilsson A; Fais S Cancer Res; 2007 Jun; 67(11):5408-17. PubMed ID: 17545622 [TBL] [Abstract][Full Text] [Related]
12. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Morishita N; Tsukahara H; Chayama K; Ishida T; Washio K; Miyamura T; Yamashita N; Oda M; Morishima T Pediatr Blood Cancer; 2012 Jul; 59(1):83-9. PubMed ID: 22183914 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Safa M; Kazemi A; Zand H; Azarkeivan A; Zaker F; Hayat P Apoptosis; 2010 Feb; 15(2):196-203. PubMed ID: 19882354 [TBL] [Abstract][Full Text] [Related]
15. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733 [TBL] [Abstract][Full Text] [Related]
16. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4. Sheikh-Zeineddini N; Safaroghli-Azar A; Salari S; Bashash D Eur J Pharmacol; 2020 Mar; 870():172821. PubMed ID: 31770526 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635 [TBL] [Abstract][Full Text] [Related]
18. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Castillo JJ; Furman M; Winer ES Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004 [TBL] [Abstract][Full Text] [Related]
19. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221 [TBL] [Abstract][Full Text] [Related]
20. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Dörrie J; Gerauer H; Wachter Y; Zunino SJ Cancer Res; 2001 Jun; 61(12):4731-9. PubMed ID: 11406544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]